TY - JOUR
T1 - Neuropsychiatric symptoms in Alzheimer's disease
AU - Lyketsos, Constantine G.
AU - Carrillo, Maria C.
AU - Ryan, J. Michael
AU - Khachaturian, Ara S.
AU - Trzepacz, Paula
AU - Amatniek, Joan
AU - Cedarbaum, Jesse
AU - Brashear, Robert
AU - Miller, David S.
N1 - Funding Information:
The Neuropsychiatric Symptoms in Alzheimer’s Disease Subcommittee of the Alzheimer’s Association Research Roundtable thanks all speakers who participated in this meeting, including Clive Ballard, MD; Neil Buckholtz, PhD; Paul Francis, PhD; Mary Ganguli, MD; Serge Gauthier, MD; Yonas Geda, MD; Laura Gitlin, PhD; Russell Katz, MD; Krista Lanctot, PhD; Thomas Laughren, MD; Gill Livingston, MD; Constantine Lyketsos, MD; Jennifer Martin, PhD; Kate de Medeiros, PhD; Paul Rosenberg, MD; Lon Schneider, MD; Gwenn Smith, PhD; David Sultzer, MD; Robert Sweet, MD; Pierre Tariot, MD; Frans Verhey, MD, PhD; Philip Wang, MD; Dan Weintraub, MD; Peter Zandi, PhD. The efforts of C.G.L. on this project were supported in part by the Johns Hopkins Alzheimer’s Disease Research Center , grant P50AG005146 . The authors also thank Tom Fagan (Science Writer) and DeLois Powe (Alzheimer’s Association) for their assistance in preparing this manuscript.
PY - 2011/9
Y1 - 2011/9
N2 - Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease and related dementias. Once thought to emerge primarily in people with late-stage disease, these symptoms are currently known to manifest commonly in very early disease and in prodromal phases, such as mild cognitive impairment. Despite decades of research, reliable treatments for dementia-associated NPS have not been found, and those that are in widespread use present notable risks for people using these medications. An Alzheimer's Association Research Roundtable was convened in the spring of 2010 to review what is known about NPS in Alzheimer's disease, to discuss classification and underlying neuropathogenesis and vulnerabilities, and to formulate recommendations for new approaches to tailored therapeutics.
AB - Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease and related dementias. Once thought to emerge primarily in people with late-stage disease, these symptoms are currently known to manifest commonly in very early disease and in prodromal phases, such as mild cognitive impairment. Despite decades of research, reliable treatments for dementia-associated NPS have not been found, and those that are in widespread use present notable risks for people using these medications. An Alzheimer's Association Research Roundtable was convened in the spring of 2010 to review what is known about NPS in Alzheimer's disease, to discuss classification and underlying neuropathogenesis and vulnerabilities, and to formulate recommendations for new approaches to tailored therapeutics.
KW - Alzheimer's disease
KW - Executive dysfunction syndrome
KW - Geriatric neuropsychiatric symptoms
KW - Mild cognitive impairment
KW - Neuropsychiatric symptom management
UR - https://www.scopus.com/pages/publications/80052311901
U2 - 10.1016/j.jalz.2011.05.2410
DO - 10.1016/j.jalz.2011.05.2410
M3 - Editorial
C2 - 21889116
AN - SCOPUS:80052311901
SN - 1552-5260
VL - 7
SP - 532
EP - 539
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 5
ER -